Corvus Pharmaceuticals Inc

CRVSNASDAQ · USD
10.60USD0.00 (-0.38%)
2210

Corvus Pharmaceuticals Inc (CRVS) Historical Volatility

CRVS's 30 day historical volatility is 67.07%, in the 60th percentile of readings over the past year. This is an average percentile, meaning Corvus Pharmaceuticals Inc shares have moved roughly in line with their typical range. CRVS's 30 day implied volatility sits at 93.86%, with an IV Rank of 63.49%, leaving IV 26.79 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking CRVS historical volatility helps you see how much Corvus Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CRVS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CRVS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CRVS's 30 day historical volatility, or CRVS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CRVS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.

Historical Volatility

HV Percentile
60thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)67.07%

HV Percentile60th

Implied Volatility (30d)93.86%

IV Rank63.49%

IV Minus HV+26.79%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →